[Legal Talk] "Korean Biopharma Licensing" (partnering with Korean Pharmaceutical and Biopharma Manufacturers Association)

-

 



Introducing my latest video partnering with the ‘Korean Pharmaceutical and Bio-pharma Manufacturers Association’ on 'Useful licensing tips for Biopharma companies'.

Youtube video link: https://youtu.be/SuscTNYxBRI?si=7NCsJG38FC05DPLm


Location: Seoul, South Korea

Comments

Post a Comment

Popular posts from this blog

Amendment of the 'Act On The Safety Of And Support For Advanced Regenerative Medicine And Advanced Biological Products' welcomed by the industry

-
Image
On the first day of this month, the Ministry of Food and Drug Safety and the biotech industry welcomed the acceptance of the bill adding 'Regenerative Medical Institutions' as human cell management by the National Assembly, amending the 'Act On The Safety Of And Support For Advanced Regenerative Medicine And Advanced Biological Products'.  Human Cell Management businesses are operators who collect, import, inspect, process, and supply human cells, which have been mostly in-house product manufacturers or the blood banks. Now that this amendment has been approved, advanced regenerative medical institutions equipped with facilities, equipment, and personnel similar to the standards for human cell management, shall also be recognized as subjects for permits for the management of human cells. This means that advanced regenerative medical institutions can supply raw materials by performing minimal procedures such as simple isolation, washing, freezing, and thawing of cells ob...
Read more

GNT Pharma's positive Phase 3 clinical trial results on 'Nelonemdaz' for stroke

-
Image
South Korean  GNT Pharma Co. Ltd announced on the 13th of this month, that administering their stroke treatment drug 'Nelonemdaz' to patients within one hour of arrival at the emergency room showed nearly a five-fold improvement in disability compared to a placebo treatment. T he chief investigator of the Phase 3 trial at Seoul Asan Hospital's Neurology Department, presented the key findings at ISC 2024 held at the Phoenix Convention Center in Arizona, USA. It has been reported that  the Phase 3 trial of Nelonemdaz targeted severe stroke patients receiving intravenous thrombolysis within 12 hours of onset. The 496 patients in this trial received medication within 7 hours of onset upon arrival at the emergency room and underwent thrombolysis simultaneously, analyzing disability improvement and safety 12 weeks later.  The efficacy of Nelonemdaz was found to be related to the time of medication administration and thrombolysis. Particularly, among 47 patients who promptly rec...
Read more

Global ADC Technology competition intensifies in South Korea

-
Image
The global competition for Antibody-Drug Conjugate (ADC) technology, a cutting-edge method in anti-cancer drug development, is intensifying. Major global pharmaceutical companies, including Pfizer, AbbVie, and Johnson & Johnson, invested significantly to secure ADC technology. This trend is also evident in South Korea, with companies like Samsung Biologics and Celltrion leading the race to obtain ADC capabilities. ADC involves attaching drugs that can attack cancer cells to antibodies, offering targeted drug delivery for anti-cancer agents. The technology is gaining attention globally, and the ADC market is expected to reach $19.8 billion by 2028. The interest in ADC further increased with the approval of 'Enhertu,' an ADC drug for breast cancer jointly developed by AstraZeneca and   Daiichi Sankyo. Major global pharmaceutical companies are actively involved in ADC technology, with Pfizer's Seagen acquisition being the largest M&A deal in the sector. Korean companie...
Read more